{"id":"halofantrine","rwe":[{"pmid":"41212758","year":"2025","title":"Primary Small Intestinal Epithelia Are Physiological Alternatives to the Caco-2 Lymphatic Transport Model.","finding":"","journal":"Molecular pharmaceutics","studyType":"Clinical Study"},{"pmid":"41012563","year":"2025","title":"Indirect Modeling of Post-Prandial Intestinal Lymphatic Uptake of Halofantrine Using PBPK Approaches: Limitations and Implications.","finding":"","journal":"Pharmaceutics","studyType":"Clinical Study"},{"pmid":"40505777","year":"2025","title":"A novel cellular tool for screening human pan-coronavirus antivirals.","finding":"","journal":"Antiviral research","studyType":"Clinical Study"},{"pmid":"40140185","year":"2025","title":"Leveraging Buprenorphine and Halofantrine as Tool Molecules to Develop a Novel Semi-Physiologically based Pharmacokinetic Model Accounting for Gastro-Intestinal Lymphatic Absorption and Enabling Cross-Species Translation.","finding":"","journal":"The AAPS journal","studyType":"Clinical Study"},{"pmid":"30000758","year":"2006","title":"Halofantrine.","finding":"","journal":"","studyType":"Clinical Study"}],"tags":[{"label":"Antimalarial","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Potassium voltage-gated channel subfamily H member 2","category":"target"},{"label":"KCNH2","category":"gene"},{"label":"P01BX01","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Falciparum malaria","category":"indication"},{"label":"Vivax malaria","category":"indication"},{"label":"Glaxosmithkline","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antimalarials","category":"pharmacology"},{"label":"Antiparasitic Agents","category":"pharmacology"},{"label":"Antiprotozoal Agents","category":"pharmacology"}],"phase":"marketed","safety":{"drugInteractions":[{"url":"/drug/high-risk-qt-prolonging-agents","drug":"High Risk QT Prolonging Agents","action":"Avoid combination","effect":"Highest Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents","source":"DrugCentral","drugSlug":"high-risk-qt-prolonging-agents"},{"url":"/drug/bedaquiline","drug":"bedaquiline","action":"Avoid combination","effect":"May interact with Bedaquiline, Halofantrine Hydrochloride","source":"DrugCentral","drugSlug":"bedaquiline"}],"contraindications":["Atrioventricular Conduction Defect","Kidney disease","Prolonged QT interval"]},"trials":[],"aliases":[],"company":"GSK","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=HALOFANTRINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:25:48.753185+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:26:08.453062+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:25:59.587402+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HALOFANTRINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:26:00.325335+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Ferriprotoporphyrin IX inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:26:00.885229+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200901/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:26:00.796962+00:00"}},"allNames":"halfan","offLabel":[],"synonyms":["halofantrine hydrochloride","halofantrine","halfan","halofantrine HCl"],"timeline":[{"date":"1992-07-24","type":"positive","source":"DrugCentral","milestone":"FDA approval (Glaxosmithkline)"}],"aiSummary":"Halofantrine (Halfan), marketed by GSK, is an antimalarial drug specifically indicated for the treatment of falciparum malaria. Its key strength lies in its unique mechanism of action, which disrupts the parasite's cell membrane potential by blocking potassium channels, setting it apart from other antimalarials. The primary risk is the upcoming key composition patent expiry in 2028, which could lead to increased competition from generics.","approvals":[{"date":"1992-07-24","orphan":true,"company":"GLAXOSMITHKLINE","regulator":"FDA"}],"brandName":"Halfan","ecosystem":[{"indication":"Falciparum malaria","otherDrugs":[{"name":"artesunate","slug":"artesunate","company":"Amivas"},{"name":"atovaquone","slug":"atovaquone","company":""},{"name":"chloroquine","slug":"chloroquine","company":"Sanofi Aventis Us"},{"name":"hydroxychloroquine","slug":"hydroxychloroquine","company":"Sanofi Aventis Us"}],"globalPrevalence":240000},{"indication":"Vivax malaria","otherDrugs":[{"name":"artesunate","slug":"artesunate","company":"Amivas"},{"name":"chloroquine","slug":"chloroquine","company":"Sanofi Aventis Us"},{"name":"hydroxychloroquine","slug":"hydroxychloroquine","company":"Sanofi Aventis Us"},{"name":"mefloquine","slug":"mefloquine","company":""}],"globalPrevalence":240000}],"mechanism":{"target":"Potassium voltage-gated channel subfamily H member 2","novelty":"Follow-on","targets":[{"gene":"KCNH2","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2"}],"modality":"Small Molecule","drugClass":"Antimalarial","explanation":"","oneSentence":"","technicalDetail":"Halofantrine specifically targets the Kv11.1 potassium channel, a voltage-gated channel that plays a crucial role in maintaining the parasite's cell membrane potential. By blocking this channel, Halofantrine prevents the parasite from generating the electrical signals necessary for its survival and replication."},"commercial":{"launchDate":"1992","_launchSource":"DrugCentral (FDA 1992-07-24, GLAXOSMITHKLINE)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1350","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=HALOFANTRINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HALOFANTRINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T13:50:43.011165","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:26:08.453529+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"abemaciclib","drugSlug":"abemaciclib","fdaApproval":"2017-09-28","patentExpiry":"Sep 28, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"alosetron","drugSlug":"alosetron","fdaApproval":"2000-02-09","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amiodarone","drugSlug":"amiodarone","fdaApproval":"1985-12-24","patentExpiry":"Mar 13, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amitriptyline","drugSlug":"amitriptyline","fdaApproval":"1961-04-07","genericCount":33,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amodiaquine","drugSlug":"amodiaquine","fdaApproval":"","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"aripiprazole","drugSlug":"aripiprazole","fdaApproval":"2002-11-15","patentExpiry":"Sep 24, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"arsenic trioxide","drugSlug":"arsenic-trioxide","fdaApproval":"2000-09-25","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"asciminib","drugSlug":"asciminib","fdaApproval":"2021-10-29","patentExpiry":"Oct 29, 2035","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"astemizole","drugSlug":"astemizole","fdaApproval":"1988-12-31","relationship":"same-target"},{"drugName":"atomoxetine","drugSlug":"atomoxetine","fdaApproval":"2002-11-26","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"genericName":"halofantrine","indications":{"approved":[{"name":"Falciparum malaria","source":"DrugCentral","snomedId":62676009,"regulator":"FDA","usPrevalence":null,"globalPrevalence":240000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency2015[INST])"},{"name":"Vivax malaria","source":"DrugCentral","snomedId":27052006,"regulator":"FDA","usPrevalence":null,"globalPrevalence":240000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency2015[INST])"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"abemaciclib","brandName":"abemaciclib","genericName":"abemaciclib","approvalYear":"2017","relationship":"same-target"},{"drugId":"alosetron","brandName":"alosetron","genericName":"alosetron","approvalYear":"2000","relationship":"same-target"},{"drugId":"amiodarone","brandName":"amiodarone","genericName":"amiodarone","approvalYear":"1985","relationship":"same-target"},{"drugId":"amitriptyline","brandName":"amitriptyline","genericName":"amitriptyline","approvalYear":"1961","relationship":"same-target"},{"drugId":"amodiaquine","brandName":"amodiaquine","genericName":"amodiaquine","approvalYear":"","relationship":"same-target"},{"drugId":"aripiprazole","brandName":"aripiprazole","genericName":"aripiprazole","approvalYear":"2002","relationship":"same-target"},{"drugId":"arsenic-trioxide","brandName":"arsenic trioxide","genericName":"arsenic trioxide","approvalYear":"2000","relationship":"same-target"},{"drugId":"asciminib","brandName":"asciminib","genericName":"asciminib","approvalYear":"2021","relationship":"same-target"},{"drugId":"astemizole","brandName":"astemizole","genericName":"astemizole","approvalYear":"1988","relationship":"same-target"},{"drugId":"atomoxetine","brandName":"atomoxetine","genericName":"atomoxetine","approvalYear":"2002","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT05532241","phase":"PHASE3","title":"Dental Biofilm Control During Orthodontic Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Rijeka","startDate":"2021-11-01","conditions":["Gingivitis","Malocclusion"],"enrollment":80,"completionDate":"2026-06-01"},{"nctId":"NCT06932523","phase":"PHASE1,PHASE2","title":"A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals","status":"RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2025-04-04","conditions":["Herpes Zoster (HZ)"],"enrollment":645,"completionDate":"2027-12-31"},{"nctId":"NCT07240558","phase":"PHASE3","title":"Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-11-03","conditions":["Influenza (Pandemic)","Avian Influenza","Vaccination"],"enrollment":120,"completionDate":"2026-12-31"},{"nctId":"NCT06675851","phase":"PHASE4","title":"Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2022-12-01","conditions":["Major Depressive Disorder (MDD)"],"enrollment":120,"completionDate":"2026-12"},{"nctId":"NCT00834795","phase":"PHASE1","title":"Carvedilol 25 mg in 36 Fasted, Healthy, Adult Subjects","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2001-12","conditions":["Healthy"],"enrollment":36,"completionDate":"2001-12"},{"nctId":"NCT00834873","phase":"PHASE1","title":"Carvedilol (25 mg) in 24 Fed, Healthy, Adult Subjects","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2001-12","conditions":["Healthy"],"enrollment":24,"completionDate":"2001-12"},{"nctId":"NCT06385600","phase":"NA","title":"Intravenous Labetalol vs Phentolamine for the Management of Severe Preeclampsia.","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-05-20","conditions":["Severe Pre-eclampsia"],"enrollment":200,"completionDate":"2026-03-20"},{"nctId":"NCT06227481","phase":"PHASE2","title":"Combined Procedures in the Treatment of Severe Acne Scars","status":"NOT_YET_RECRUITING","sponsor":"Al-Azhar University","startDate":"2024-03-01","conditions":["Atrophic Acne Scar"],"enrollment":48,"completionDate":"2026-03-31"},{"nctId":"NCT06017167","phase":"PHASE2","title":"Prophylaxis Against Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-09-15","conditions":["Postoperative Nausea and Vomiting","Laparoscopic Cholecystectomy"],"enrollment":70,"completionDate":"2023-10"},{"nctId":"NCT05082688","phase":"PHASE2","title":"Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2021-09-20","conditions":["Influenza","Herpes Zoster"],"enrollment":148,"completionDate":"2023-05-17"},{"nctId":"NCT04054830","phase":"PHASE4","title":"Steroids and/ or Non-steroidal Anti-inflammatory Drugs in the Postoperative Regime After Trabeculectomy.","status":"UNKNOWN","sponsor":"Rigshospitalet, Denmark","startDate":"2019-08-01","conditions":["Glaucoma"],"enrollment":70,"completionDate":"2023-07"},{"nctId":"NCT04592016","phase":"NA","title":"Evaluate the Ability of dOFM for BE Testing of Topically Applied Diclofenac Sodium Products in Healthy Subjects","status":"COMPLETED","sponsor":"Joanneum Research Forschungsgesellschaft mbH","startDate":"2020-10-08","conditions":["Healthy"],"enrollment":22,"completionDate":"2021-08-11"},{"nctId":"NCT05120206","phase":"NA","title":"The Impact of Cigarette Smoking on Periodontal Therapy","status":"COMPLETED","sponsor":"University of Bergen","startDate":"2012-04-01","conditions":["Periodontitis","Cigarette Smoking"],"enrollment":80,"completionDate":"2015-03-01"},{"nctId":"NCT01742702","phase":"","title":"HaemoDYNAMICs in Primary and Secondary Hypertension","status":"UNKNOWN","sponsor":"Tampere University","startDate":"2006-05-25","conditions":["Primary Hypertension","Secondary Hypertension","Aortic Stenosis","Renal Insufficiency"],"enrollment":2000,"completionDate":"2025-12-31"},{"nctId":"NCT04942262","phase":"PHASE3","title":"Oral Health-related Quality of Life and Masticatory Function After Using Denture Adhesive and Denture Liner","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2019-01-31","conditions":["Complete Denture","Complete Edentulism"],"enrollment":80,"completionDate":"2020-04-30"},{"nctId":"NCT04767178","phase":"","title":"Pain Management During Screening for Retinopathy of Prematurity","status":"COMPLETED","sponsor":"Istanbul Medeniyet University","startDate":"2020-01-01","conditions":["Retinopathy of Prematurity","Pain Management"],"enrollment":44,"completionDate":"2020-08-15"},{"nctId":"NCT00662012","phase":"PHASE2","title":"Sodium Stibogluconate Treatment of Leishmaniasis","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2002-06","conditions":["Leishmaniasis"],"enrollment":414,"completionDate":"2007-12"},{"nctId":"NCT04642001","phase":"NA","title":"Association of Two Desensitizing Protocols to Control Dentinal Hypersensitivity in Non-carious Lesions","status":"COMPLETED","sponsor":"Universidade Federal do Para","startDate":"2019-08-07","conditions":["Dental Hypersensitivity"],"enrollment":24,"completionDate":"2020-11-05"},{"nctId":"NCT04620018","phase":"NA","title":"Comparison of Three Antibiotic Protocols in Prevention of Infection in Dental Implant Surgery","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2016-09-30","conditions":["Dental Implant Failed"],"enrollment":450,"completionDate":"2020-09-01"},{"nctId":"NCT02400879","phase":"NA","title":"Remifentanil Anesthesia and Postoperative BIS in Cardiac Surgery","status":"COMPLETED","sponsor":"Konkuk University Medical Center","startDate":"2015-10","conditions":["Cardiovascular Disease"],"enrollment":38,"completionDate":"2016-10"},{"nctId":"NCT04214938","phase":"PHASE4","title":"Hypertonic Saline Enhances The Field of View of Clinicians and Ease of Procedures","status":"COMPLETED","sponsor":"Selcuk University","startDate":"2016-02-01","conditions":["Nasopharyngeal Diseases"],"enrollment":200,"completionDate":"2019-01-01"},{"nctId":"NCT00657618","phase":"PHASE1,PHASE2","title":"Use of Sodium Stibogluconate as a Treatment for Leishmaniasis","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2004-10","conditions":["Leishmaniasis"],"enrollment":77,"completionDate":"2015-04"},{"nctId":"NCT02207816","phase":"PHASE3","title":"An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-18","conditions":["Malaria"],"enrollment":3084,"completionDate":"2017-01-31"},{"nctId":"NCT03465488","phase":"NA","title":"Validating Egg-based Diagnostics and Molecular Markers for the Spread of Anthelmintic Resistance","status":"COMPLETED","sponsor":"University Ghent","startDate":"2016-08-15","conditions":["Soil-transmitted Helminth Infections"],"enrollment":1000,"completionDate":"2019-09-01"},{"nctId":"NCT00866619","phase":"PHASE3","title":"Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03-27","conditions":["Malaria"],"enrollment":15459,"completionDate":"2014-01-31"},{"nctId":"NCT02069392","phase":"NA","title":"Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2015-01","conditions":["Schizophrenia","Schizoaffective Disorder"],"enrollment":31,"completionDate":"2017-06"},{"nctId":"NCT01599364","phase":"PHASE4","title":"Atazanavir/r + Lamivudine Dual Therapy","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2014-04","conditions":["Human Immunodeficiency Virus"],"enrollment":266,"completionDate":"2018-02-23"},{"nctId":"NCT01345240","phase":"PHASE3","title":"Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-17","conditions":["Malaria","Malaria Vaccines"],"enrollment":705,"completionDate":"2017-02-09"},{"nctId":"NCT02003703","phase":"PHASE3","title":"Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV .","status":"COMPLETED","sponsor":"Universidad de Valparaiso","startDate":"2015-05","conditions":["Hepatitis B","HIV"],"enrollment":107,"completionDate":"2018-12"},{"nctId":"NCT01907217","phase":"PHASE4","title":"Enhancing the Effectiveness of Electroconvulsive Therapy in Severe Depression","status":"COMPLETED","sponsor":"St Patrick's Hospital, Ireland","startDate":"2008-05","conditions":["Depression"],"enrollment":138,"completionDate":"2015-04"},{"nctId":"NCT02002156","phase":"PHASE4","title":"A Study of the Interaction Between BCG And MenC Immunisation: BAM","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-06-20","conditions":["BCG Infection","Reaction - Vaccine","Immune Response"],"enrollment":28,"completionDate":"2018-06-27"},{"nctId":"NCT01730378","phase":"PHASE4","title":"Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-12-05","conditions":["Influenza"],"enrollment":131,"completionDate":"2013-12-17"},{"nctId":"NCT00057330","phase":"PHASE3","title":"HerpeVac Trial for Young Women","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-01-14","conditions":["Herpes Simplex Infection"],"enrollment":8323,"completionDate":"2009-08-22"},{"nctId":"NCT00541970","phase":"PHASE1","title":"Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-17","conditions":["Infections, Papillomavirus"],"enrollment":961,"completionDate":"2013-03-18"},{"nctId":"NCT00426361","phase":"PHASE3","title":"Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-13","conditions":["Infections, Papillomavirus"],"enrollment":751,"completionDate":"2008-07-25"},{"nctId":"NCT01155037","phase":"PHASE2","title":"Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults","status":"COMPLETED","sponsor":"Oswaldo Cruz Foundation","startDate":"2010-03","conditions":["HIV Infection"],"enrollment":450,"completionDate":"2012-04"},{"nctId":"NCT01339247","phase":"PHASE1","title":"Paxil CR Bioequivalence Study Brazil - Fed Administration","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-20","conditions":["Depressive Disorder"],"enrollment":60,"completionDate":"2009-11-16"},{"nctId":"NCT01316926","phase":"PHASE1","title":"Paxil CR Bioequivalence Study Brazil","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-09","conditions":["Depressive Disorder"],"enrollment":60,"completionDate":"2009-10-05"},{"nctId":"NCT02548078","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-11-09","conditions":["Virus Diseases"],"enrollment":600,"completionDate":"2017-05-15"},{"nctId":"NCT02015169","phase":"PHASE2","title":"Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2012-07-09","conditions":["HER2-positive Gastric Cancer Patients With Liver Metastasis"],"enrollment":32,"completionDate":"2017-11-17"},{"nctId":"NCT02485301","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-07-15","conditions":["Virus Diseases"],"enrollment":3024,"completionDate":"2016-12-23"},{"nctId":"NCT02455401","phase":"NA","title":"Effect of Remifentanil on Postoperative Vomiting in Pediatric Strabismus Surgery","status":"COMPLETED","sponsor":"Inje University","startDate":"2015-05","conditions":["Strabismus"],"enrollment":60,"completionDate":"2017-11"},{"nctId":"NCT00815282","phase":"PHASE4","title":"Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease","status":"COMPLETED","sponsor":"N.M. Wulffraat","startDate":"2009-02","conditions":["Juvenile Idiopathic Arthritis","Systemic Lupus Erythematosus","Juvenile Dermatomyositis"],"enrollment":135,"completionDate":"2015-01"},{"nctId":"NCT03325400","phase":"NA","title":"Cytogenetic Damage in Buccal Cells Caused by Toothpaste","status":"COMPLETED","sponsor":"University of Split, School of Medicine","startDate":"2016-01-01","conditions":["Toxicity"],"enrollment":40,"completionDate":"2016-07-20"},{"nctId":"NCT02446496","phase":"PHASE4","title":"A Bioequivalence Study of Cefadroxil Film Coated Tablets After A Single Oral Dose Administration to Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-03-31","conditions":["Infections, Urinary Tract"],"enrollment":24,"completionDate":"2014-04-08"},{"nctId":"NCT01853956","phase":"PHASE1","title":"Bioequivalence Trial of Alprazolam 0.25 mg Tablets","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12-02","conditions":["Anxiety Disorders"],"enrollment":28,"completionDate":"2010-12-10"},{"nctId":"NCT00729430","phase":"PHASE3","title":"Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2008-08","conditions":["Myocardial Infarction","Death, Sudden, Cardiac"],"enrollment":358,"completionDate":"2014-07"},{"nctId":"NCT00861939","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"2004-03","conditions":["Depression"],"enrollment":28,"completionDate":"2004-04"},{"nctId":"NCT00864981","phase":"PHASE1","title":"A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"2005-09","conditions":["Depression"],"enrollment":32,"completionDate":"2005-10"},{"nctId":"NCT00947128","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"2004-09","conditions":["Nausea","Vomiting"],"enrollment":26,"completionDate":"2004-10"},{"nctId":"NCT00946387","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"2004-09","conditions":["Nausea","Vomiting"],"enrollment":26,"completionDate":"2004-09"},{"nctId":"NCT00490061","phase":"PHASE2","title":"Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy","status":"TERMINATED","sponsor":"Quynh-Thu Le","startDate":"2007-07","conditions":["Head and Neck Cancer","Carcinoma, Squamous Cell","Head and Neck Cancers"],"enrollment":17,"completionDate":"2016-06"},{"nctId":"NCT01593514","phase":"PHASE4","title":"Understanding the Immune Response to Two Different Meningitis Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-12","conditions":["Meningitis","Meningococcal Disease","Septicaemia"],"enrollment":20,"completionDate":""},{"nctId":"NCT00383227","phase":"PHASE3","title":"Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1999-12","conditions":["Hepatitis B"],"enrollment":165,"completionDate":"2000-11"},{"nctId":"NCT00699764","phase":"PHASE3","title":"Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1996-03","conditions":["Herpes Simplex"],"enrollment":2491,"completionDate":"1999-10"},{"nctId":"NCT00827554","phase":"PHASE2,PHASE3","title":"The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2008-12","conditions":["Hepatocellular Carcinoma"],"enrollment":100,"completionDate":"2011-10"},{"nctId":"NCT01850589","phase":"NA","title":"Comparison of Conservative and Aggressive Smoking Cessation Treatment Strategies in a Vascular Surgery Office Practice","status":"TERMINATED","sponsor":"Northwell Health","startDate":"2011-03","conditions":["Smoking Cessation"],"enrollment":44,"completionDate":"2013-01"},{"nctId":"NCT02086838","phase":"PHASE4","title":"Iron Supplementation Using Total Dose Infusion and Oral Routes for Treatment of Iron Deficiency Anemia in Pregnancy","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2013-07","conditions":["Treatment of Iron Deficiency Anemia in Pregnancy"],"enrollment":212,"completionDate":"2014-12"},{"nctId":"NCT02296255","phase":"PHASE4","title":"Effect of HPV Vaccination on Women Aged 25 Years","status":"COMPLETED","sponsor":"Cancer Prevention and Research Institute, Italy","startDate":"2010-04","conditions":["Cervical Cancer"],"enrollment":832,"completionDate":"2013-07"},{"nctId":"NCT01894269","phase":"PHASE4","title":"Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2013-07","conditions":["Hepatocellular Carcinoma"],"enrollment":200,"completionDate":"2016-07"},{"nctId":"NCT01861613","phase":"PHASE4","title":"Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students","status":"COMPLETED","sponsor":"Hui Zhuang","startDate":"2009-09","conditions":["Hepatitis B","Immune Response","Seroprevalence"],"enrollment":2040,"completionDate":""},{"nctId":"NCT01394497","phase":"PHASE2","title":"Use of N-Acetylcysteine During Liver Procurement","status":"COMPLETED","sponsor":"Azienda Ospedaliera di Padova","startDate":"2006-12","conditions":["Liver Failure","Liver Failure, Acute","Liver Diseases","Carcinoma, Hepatocellular","Liver Neoplasms"],"enrollment":140,"completionDate":"2009-07"},{"nctId":"NCT00739128","phase":"NA","title":"Response to Hepatitis B Vaccine in Celiac Disease Patients","status":"TERMINATED","sponsor":"Shaare Zedek Medical Center","startDate":"2009-02","conditions":["Celiac Disease"],"enrollment":210,"completionDate":"2011-03"},{"nctId":"NCT01279499","phase":"PHASE2,PHASE3","title":"Sevoflurane Versus Intravenous Anaesthetic Agents in Morbid Obese Patients","status":"UNKNOWN","sponsor":"University of Patras","startDate":"2010-04","conditions":["Morbid Obesity"],"enrollment":100,"completionDate":"2011-07"},{"nctId":"NCT01131702","phase":"PHASE1","title":"Bioequivalency Study of Ranitidine Tablets 300 mg of Dr. Reddy's Under Fasting Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2003-01","conditions":["Healthy"],"enrollment":24,"completionDate":"2003-03"},{"nctId":"NCT01022905","phase":"PHASE4","title":"Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2009-11","conditions":["HIV Infection","Rheumatic Disease","Cancer","Transplant","Pediatrics"],"enrollment":1141,"completionDate":"2010-02"},{"nctId":"NCT00675740","phase":"PHASE4","title":"Physical Exercise Versus Rosiglitazone in CAD and Prediabetes","status":"COMPLETED","sponsor":"University of Leipzig","startDate":"2004-01","conditions":["Impaired Glucose Tolerance"],"enrollment":45,"completionDate":"2007-02"},{"nctId":"NCT00299455","phase":"PHASE4","title":"Amoxicillin Clavulanate in Treatment of Acute Otitis Media","status":"UNKNOWN","sponsor":"University of Turku","startDate":"2006-03","conditions":["Acute Otitis Media"],"enrollment":320,"completionDate":"2009-03"},{"nctId":"NCT00778050","phase":"NA","title":"Bioequivalence Study of Amoxicillin Dispersible 600 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2002-10","conditions":["Healthy"],"enrollment":26,"completionDate":"2002-12"},{"nctId":"NCT00699231","phase":"PHASE1","title":"Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1992-02","conditions":["Hepatitis B"],"enrollment":30,"completionDate":"1992-12"},{"nctId":"NCT00698087","phase":"PHASE3","title":"Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1995-01","conditions":["Hepatitis B"],"enrollment":60,"completionDate":"1996-02"},{"nctId":"NCT00697970","phase":"PHASE3","title":"Evaluation of Immunogenicity and Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1993-11","conditions":["Hepatitis B"],"enrollment":321,"completionDate":"1995-04"},{"nctId":"NCT00697840","phase":"PHASE3","title":"Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1995-06","conditions":["Hepatitis B"],"enrollment":150,"completionDate":"1996-01"},{"nctId":"NCT00697931","phase":"PHASE3","title":"Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1997-05","conditions":["Hepatitis B"],"enrollment":116,"completionDate":"1998-06"},{"nctId":"NCT00697242","phase":"PHASE3","title":"Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1994-01","conditions":["Hepatitis B"],"enrollment":362,"completionDate":"1995-11"},{"nctId":"NCT00697125","phase":"PHASE2","title":"Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1993-06","conditions":["Hepatitis B"],"enrollment":60,"completionDate":"1994-07"},{"nctId":"NCT00508833","phase":"PHASE1,PHASE2","title":"Safety and Efficacy of SmithKline Beecham (GlaxoSmithKline [GSK]) Biologicals' Candidate Adjuvanted Vaccines (287615)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-03","conditions":["Hepatitis B Disease"],"enrollment":200,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000148563","MMSL":"17110","NDDF":"003977","UNII":"Q2OS4303HZ","VUID":"4021108","CHEBI":"CHEBI:5612","VANDF":"4021108","INN_ID":"4749","RXNORM":"151844","UMLSCUI":"C0120726","chemblId":"CHEMBL1200901","ChEMBL_ID":"CHEMBL1107","KEGG_DRUG":"D02485","DRUGBANK_ID":"DB01218","PUBCHEM_CID":"37393","SNOMEDCT_US":"108681001","IUPHAR_LIGAND_ID":"10019","SECONDARY_CAS_RN":"36167-63-2","MESH_SUPPLEMENTAL_RECORD_UI":"C023768"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1992-","companyName":"GSK","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"6%"},"publicationCount":623,"therapeuticAreas":["Rare Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"P01BX01","allCodes":["P01BX01"]},"biosimilarFilings":[],"originalDeveloper":"Glaxosmithkline","recentPublications":[{"date":"2025 Dec 1","pmid":"41212758","title":"Primary Small Intestinal Epithelia Are Physiological Alternatives to the Caco-2 Lymphatic Transport Model.","journal":"Molecular pharmaceutics"},{"date":"2025 Sep 22","pmid":"41012563","title":"Indirect Modeling of Post-Prandial Intestinal Lymphatic Uptake of Halofantrine Using PBPK Approaches: Limitations and Implications.","journal":"Pharmaceutics"},{"date":"2025 Aug","pmid":"40505777","title":"A novel cellular tool for screening human pan-coronavirus antivirals.","journal":"Antiviral research"},{"date":"2025 Mar 26","pmid":"40140185","title":"Leveraging Buprenorphine and Halofantrine as Tool Molecules to Develop a Novel Semi-Physiologically based Pharmacokinetic Model Accounting for Gastro-Intestinal Lymphatic Absorption and Enabling Cross-Species Translation.","journal":"The AAPS journal"},{"date":"2006","pmid":"30000758","title":"Halofantrine.","journal":""}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"GSK","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"1992","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1992-07-24T00:00:00.000Z","mah":"GLAXOSMITHKLINE","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:26:08.453529+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}